Clinical trials of low-molecular-weight heparins in cardiology.
Our understanding of the pathophysiology of acute coronary syndromes is evolving as the role of prognostic coagulation markers and the different effects unfractionated heparin and low-molecular-weight heparins have on these coagulation markers are investigated. The results of recent clinical trials of low-molecular-weight heparins in acute coronary syndromes are summarized, and an economic evaluation of enoxaparin for these indications is reviewed.
Spinler
S A
SA
Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Pennsylvania 19104, USA.
D000208:Acute Disease; D015415:Biomarkers / Q000032:analysis; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy* / Q000191:economics; D017984:Enoxaparin / Q000191:economics / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000191:economics / Q000627:therapeutic use*; D006801:Humans
D015415:Biomarkers; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight